A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer

Kerslake, Rachel; Hall, Marcia; Vagnarelli, Paola; Jeyaneethi, Jeyarooban; Randeva, Harpal S.; Pados, George; Kyrou, Ioannis; Karteris, Emmanouíl

doi:10.3892/ol.2021.12911

Cited by 22 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Available evidence indicates that asprosin immunoreactivity is considerably raised in malignant mesothelioma, and can thus serve as its possible diagnostic marker [13]. Recently, Kerslake et al [11] reported that asprosin influences fertility and steroidogenesis in healthy ovaries and may act as a glucogenic peptide in ovarian cancer, whereas Li [18] found that FBN1 (asprosin encoded gene) may be a potential colon cancer marker. According to [4] , reduced asprosin levels may also be the cause of cancerrelated anorexia and cachexia syndrome in patients with gastric cancer, colorectal cancer, and other cancers.…”

Section: Discussionmentioning

confidence: 99%

“…suggesting that it may play a role as a glucogenic peptide in ovarian cancer [11]. However, it remains to be established whether asprosin levels are changed in patients diagnosed with BC.…”

Section: Introductionmentioning

confidence: 99%

“…Although the relationship between asprosin and cancer is insufficiently studied, extant findings indicate that asprosin immunoreactivity is increased in malignant mesothelioma [13], suggesting that it may play a role as a glucogenic peptide in ovarian cancer [11]. However, it remains to be established whether asprosin levels are changed in patients diagnosed with BC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A novel adipose hormone asprosin as a potential breast cancer marker

Özcan

Yıldırım

Yur

et al. 2021

Preprint

View full text Add to dashboard Cite

PurposeAsprosin is a recently discovered hormone released by white adipose tissue (WAT) that is typically significantly elevated in obese adults. Consequently, the adverse effects of increasing WAT in obesity during breast cancer (BC) development and progression have attracted interest of researchers and clinical practitioners. Thus, the aim of the present study was to determine whether the asprosin levels are associated with the probability of women having BC. MethodsThe study sample comprised of 45 female patients diagnosed with invasive BC and 42 healthy women that served as controls. Asprosin serum level was quantified in all subjects by ELISA, whereas serum levels of CEA and CA 15–3 were measured using an immunology analyzer. The potential association between asprosin and BC was examined through logistic regression analyses, while samples provided by BC patients were further subjected to ROC analysis to assess the diagnostic accuracy of asprosin. ResultsAsprosin levels were significantly higher in BC patients compared to healthy controls (2.38 ± 0.54 vs. 1.39 ± 0.53 ng/mL, p < 0.001). Multivariable analysis showed that the increased asprosin levels were associated with a significantly higher risk of breast cancer after adjustments for family history of breast and/or gynecological cancer, dyslipidemia, and BMI (odds ratio = 157.92; 95% confidence interval = 17.22−1447.96). When 1.78 ng/mL was adopted as the cut-off value, AUC, sensitivity, and specificity of asprosin for BC were 0.943, 91.1%, and 88.1%, respectively. ConclusionsOur findings demonstrate that asprosin is elevated in BC and can thus be an appropriate candidate for breast cancer diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…suggesting that it may play a role as a glucogenic peptide in ovarian cancer [11]. However, it remains to be established whether asprosin levels are changed in patients diagnosed with BC.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel adipose hormone asprosin as a potential breast cancer marker

Özcan

Yıldırım

Yur

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, no significant difference was identified between cancer patients and non-cancer patients [Du et al, 2021]. In ovarian cancer, asprosin was found to be differentially expressed across all different histological subtypes [Kerslake et al, 2021]. Moreover, apoptosis is a natural defense system against neoplastic growth [Hanahan and Weinberg, 2011].…”

Section: Possible Role Of Asprosin In Cancer and Cellular Apoptosismentioning

confidence: 97%

Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease

Ovalı

Bozgeyik

2022

Mol Syndromol

View full text Add to dashboard Cite

Background: Asprosin is a novel fasting-induced, glucogenic, and orexigenic protein hormone that is discovered with the help of genetic studies in patients with neonatal progeroid syndrome. Asprosin is encoded by the penultimate 2 exons (65 and 66) of the fibrillin 1 (FBN1) gene. Profibrillin 1 is the unprocessed protein product of FBN1 and undergoes a proteolytic cleavage by furin enzyme to produce mature fibrillin 1 and asprosin. The main organ responsible for the asprosin production seems to be white adipose tissue. Summary: Asprosin promotes hepatic glucose release in the liver and appetite stimulation in the hypothalamus through activation of the cAMP signaling circuitry through interacting with its G protein-coupled receptor, called OR4M1. Increasing mass of evidence suggests that asprosin is involved in the development and progression of various clinical conditions including diabetes, obesity, cardiomyopathy, cancer, and polycystic ovarian syndrome. It regulates various cellular and physiological processes such as appetite stimulation, glucose release, insulin secretion, apoptotic cell death, and inflammatory response. In this review, we discuss the current literature on asprosin and try to shed light on the yet undiscovered functions of asprosin. Key Message: Asprosin is a key regulatory factor for preserving the homeostasis of energy metabolism.

show abstract

“…Appropriate ethical approvals were in place for the use of these tissue samples, including using the Health Insurance Portability and Accountability Act (HIPAA) approved protocols. The protocol below is a brief summary, which is fully elaborated in Kerslake et al [12]. Primarily, the slide underwent de-paraffinization and antigen retrieval.…”

Section: Immunohistochemistry (Ihc)mentioning

confidence: 99%

Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro

Filipe

Katopodis

Chudasama

et al. 2022

JPM

Self Cite

View full text Add to dashboard Cite

Background: DNA double strand breaks can affect genome integrity potentially leading to cancer. RAD51-associated protein 1 (RAD51AP1), an accessory protein to RAD51, is critical for homologous recombination, a key DNA damage response pathway. Emerging studies indicate a novel role for RAD51AP1 in carcinogenesis. Here we provide additional insight into the role of RAD51AP1 in ovarian cancer (OvCa). Methods: Gene expression and patient phenotype data were obtained from TCGA and GTEX project consortia for bioinformatics analysis. Immunohistochemistry of OvCa tissue microarray was undertaken. Functional analyses were performed in a SKOV3 OvCa cell line with down-regulation of RAD51AP1 using siRNA. Results: RAD51AP1 is overexpressed at gene level in primary and recurrent OvCa compared to controls. At protein level, RAD51AP1 was up-regulated in low grade serous tumors compared to high grade OvCa. There was higher expression of RAD51AP1 in OvCa metastatic to lymph nodes compared to primary cancer samples. Gene enrichment analyses identified 12 differentially expressed genes (DEGs) related to OvCa, eight of which are also common in tissue from patients with type 2 diabetes mellitus (T2DM). Conclusions: RAD51AP1 is overexpressed in OvCa, Given the link between OvCa and T2DM, the eight-gene signature shows potential for predictive value.

show abstract

A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer

Cited by 22 publications

References 47 publications

A novel adipose hormone asprosin as a potential breast cancer marker

A novel adipose hormone asprosin as a potential breast cancer marker

Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the <b><i>FBN1</i></b> Gene, in Health and Disease

Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro

Contact Info

Product

Resources

About